Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

This year in review of 2024 milestones in non–small cell lung cancer (NSCLC) features coverage of the LAURA trial presented in June at the American Society of Clinical Oncology meeting in ...

Lung cancer is the most common cause of cancer-related deaths in both men and women, making up about 20% of all cancer deaths. It is mainly divided into two types: non-small cell lung cancer ...

How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.

In patients with advanced non–small cell lung cancer without actionable genomic alterations, whose tumors progress during or after first-line chemoimmunotherapy, second-line monotherapy with docetaxel ...

Chemotherapy is a treatment that may be used for non-small cell lung cancer. It’s often used in combination with other treatment types. Chemotherapy is associated with a variety of risks and ...

Stage 3 non-small cell lung cancer has spread to nearby tissues and lymph nodes but not to more distant tissues. Most people with this stage have lung cancer symptoms. Treatment can depend on ...

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer. Antibody-drug conjugates (ADCS) have emerged as ...